Galactosemia type I, or galactose-1-phosphate uridyltransferase deficiency, is a congenital error of metabolism with autosomal recessive inheritance caused by pathogenic variants in the GALT gene. The reduction or absence of GALT activity prevents the metabolism of galactose from lactose, leading to the accumulation of galactose-1-phosphate and other toxic metabolites, with a risk of liver, kidney, ocular, and neurological damage from the neonatal period.
Galactosemia type 1 (GALT gene)
The GALT gene encodes the enzyme galactose-1-phosphate uridyltransferase, a key protein in the Leloir pathway, responsible for converting galactose-1-phosphate and UDP-glucose into UDP-galactose and glucose-1-phosphate. This pathway allows galactose to be used as an energy source and maintains the balance of sugars necessary for the synthesis of glycoconjugates. Galactose mainly comes from lactose present in breast milk, infant formulas, and dairy products.
When biallelic pathogenic variants exist in GALT, enzyme activity can be severely reduced, as in classic galactosemia, or partially preserved in variant clinical or biochemical forms. The metabolic block leads to the accumulation of galactose-1-phosphate in erythrocytes and tissues, as well as galactitol and galactonate, which explains the hepatic, renal, ocular, and cerebral toxicity. Inheritance is autosomal recessive. The incidence of classic galactosemia is approximately between 1 in 30,000 and 60,000 live births, with variability between populations; some variants, such as p.Gln188Arg, are frequent in people of European descent, while p.Ser135Leu has been described more frequently in people of African descent.
Symptoms
Onset usually occurs in the first few days of life, after exposure to breast milk or formula containing lactose. Untreated newborns may present with feeding refusal, vomiting, diarrhea, lethargy, jaundice, hepatomegaly, hypoglycemia, coagulation abnormalities, and liver failure. The risk of sepsis also increases, particularly due to Escherichia coli, and cataracts may appear. Although early dietary treatment prevents acute complications and neonatal mortality, some individuals develop long-term complications, such as speech disorders, learning difficulties, motor impairments, tremor or ataxia, and, in women, primary ovarian insufficiency.
Disease management
Management should be initiated immediately upon clinical suspicion or a positive newborn screening, and consists of removing galactose and lactose from the diet, substituting breast milk or conventional formula with lactose-free formulas, and avoiding dairy products and other foods or medications with significant sources of galactose. This restriction is lifelong, although tolerance to small non-dairy sources may be individualized under specialized supervision. Follow-up includes monitoring of galactose-1-phosphate and galactitol, hepatic, ophthalmological, nutritional, developmental, and speech assessment, as well as monitoring of bone health and ovarian function in women. There is currently no approved enzyme therapy to replace GALT activity.
Genes analyzed
Bibliography
Timson DJ. The molecular basis of galactosemia - Past, present and future. Gene. 2016 Sep 10;589(2):133-41.
Katler QS, Stepien KM, Paull N, et al. A multinational study of acute and long-term outcomes of Type 1 galactosemia patients who carry the S135L (c.404C > T) variant of GALT. J Inherit Metab Dis. 2022 Nov;45(6):1106-1117.
Canson DM, Silao CLT, Caoili SEC. Functional analysis of GALT variants found in classic galactosemia patients using a novel cell-free translation method. JIMD Rep. 2019 May 9;48(1):60-66.
Iwasawa S, Kikuchi A, Wada Y, et al. The prevalence of GALM mutations that cause galactosemia: A database of functionally evaluated variants. Mol Genet Metab. 2019 Apr;126(4):362-367.
